<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000822'>Hypertension</z:hpo> is a well known risk factor for cerebral small vessel disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVD</z:e>) characterized by MRI white matter hyperintensities called "leukoaraiosis" </plain></SENT>
<SENT sid="1" pm="."><plain>However, the molecular basis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVD</z:e> remains to be elucidated </plain></SENT>
<SENT sid="2" pm="."><plain>Both twin and family studies have shown that leukoaraiosis is the most heritable cerebrovascular phenotype with a heritability estimated to be between 55% and 71%, suggesting genetic factors for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Cerebral <z:hpo ids='HP_0000007'>autosomal recessive</z:hpo> <z:e sem="disease" ids="C0852949" disease_type="Disease or Syndrome" abbrv="">arteriopathy</z:e> with subcortical <z:mpath ids='MPATH_124'>infarcts</z:mpath> and <z:hpo ids='HP_0002352'>leukoencephalopathy</z:hpo> (CARASIL) is hereditary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVD</z:e> lacking <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>We have recently identified the causative gene, FHtrA1, for CARASIL by genome-wide linkage study and a candidate gene approach </plain></SENT>
<SENT sid="5" pm="."><plain>HtrA1 is a serine protease that represses signaling by TGF-β family members </plain></SENT>
<SENT sid="6" pm="."><plain>We found that mutated HtrA1 did not repress signaling by the TGF-β family members (BMP2, BMP4, and TGF-β1), resulting in vascular <z:mp ids='MP_0003045'>fibrosis</z:mp> with synthesis of extracellular matrix proteins </plain></SENT>
<SENT sid="7" pm="."><plain>Our results indicate that <z:hpo ids='HP_0000734'>disinhibition</z:hpo> of TGF-β signaling underlies the molecular basis of CARASIL </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's syndrome</z:e> is an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disorder</z:e> caused by <z:hpo ids='HP_0000734'>disinhibition</z:hpo> of TGF-β signaling associated with FBN1 mutations </plain></SENT>
<SENT sid="9" pm="."><plain>In a small cohort study, <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi>-receptor blockers (ARBs) therapy in patients with <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's syndrome</z:e> significantly slowed the rate of progressive <z:hpo ids='HP_0002616'>aortic-root dilatation</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>This study provides a potential for developing a therapy targeting TGF-β signaling for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVD</z:e> </plain></SENT>
</text></document>